vs
Celsius Holdings, Inc.（CELH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Celsius Holdings, Inc.的1.1倍（$772.1M vs $721.6M），Revvity净利率更高（12.7% vs 3.4%，领先9.3%），Celsius Holdings, Inc.同比增速更快（117.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-130.0M），过去两年Celsius Holdings, Inc.的营收复合增速更高（42.4% vs 9.0%）
Celsius Holdings Inc.是美国功能饮品企业，旗下Celsius品牌主打健身饮料、能量饮品系列，产品主打健康定位，公司CEO曾表示这一差异化优势是品牌取得市场成功的核心原因。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CELH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$721.6M
营收增速更快
CELH
高出111.4%
5.9%
净利率更高
RVTY
高出9.3%
3.4%
自由现金流更多
RVTY
多$291.8M
$-130.0M
两年增速更快
CELH
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $721.6M | $772.1M |
| 净利润 | $24.7M | $98.4M |
| 毛利率 | 47.4% | — |
| 营业利润率 | 3.6% | 14.5% |
| 净利率 | 3.4% | 12.7% |
| 营收同比 | 117.2% | 5.9% |
| 净利润同比 | 231.1% | 3.9% |
| 每股收益（稀释后） | $0.04 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CELHRVTY
| Q4 25 | $721.6M | $772.1M | ||
| Q3 25 | $725.1M | $698.9M | ||
| Q2 25 | $739.3M | $720.3M | ||
| Q1 25 | $329.3M | $664.8M | ||
| Q4 24 | $332.2M | $729.4M | ||
| Q3 24 | $265.7M | $684.0M | ||
| Q2 24 | $402.0M | $691.7M | ||
| Q1 24 | $355.7M | $649.9M |
净利润CELHRVTY
| Q4 25 | $24.7M | $98.4M | ||
| Q3 25 | $-61.0M | $46.7M | ||
| Q2 25 | $99.9M | $53.9M | ||
| Q1 25 | $44.4M | $42.2M | ||
| Q4 24 | $-18.9M | $94.6M | ||
| Q3 24 | $6.4M | $94.4M | ||
| Q2 24 | $79.8M | $55.4M | ||
| Q1 24 | $77.8M | $26.0M |
毛利率CELHRVTY
| Q4 25 | 47.4% | — | ||
| Q3 25 | 51.3% | 53.6% | ||
| Q2 25 | 51.5% | 54.5% | ||
| Q1 25 | 52.3% | 56.5% | ||
| Q4 24 | 50.2% | — | ||
| Q3 24 | 46.0% | 56.3% | ||
| Q2 24 | 52.0% | 55.7% | ||
| Q1 24 | 51.2% | 54.6% |
营业利润率CELHRVTY
| Q4 25 | 3.6% | 14.5% | ||
| Q3 25 | -11.0% | 11.7% | ||
| Q2 25 | 19.3% | 12.6% | ||
| Q1 25 | 15.8% | 10.9% | ||
| Q4 24 | -5.6% | 16.3% | ||
| Q3 24 | -1.2% | 14.3% | ||
| Q2 24 | 23.4% | 12.4% | ||
| Q1 24 | 23.4% | 6.8% |
净利率CELHRVTY
| Q4 25 | 3.4% | 12.7% | ||
| Q3 25 | -8.4% | 6.7% | ||
| Q2 25 | 13.5% | 7.5% | ||
| Q1 25 | 13.5% | 6.4% | ||
| Q4 24 | -5.7% | 13.0% | ||
| Q3 24 | 2.4% | 13.8% | ||
| Q2 24 | 19.8% | 8.0% | ||
| Q1 24 | 21.9% | 4.0% |
每股收益（稀释后）CELHRVTY
| Q4 25 | $0.04 | $0.86 | ||
| Q3 25 | $-0.27 | $0.40 | ||
| Q2 25 | $0.33 | $0.46 | ||
| Q1 25 | $0.15 | $0.35 | ||
| Q4 24 | $-0.10 | $0.77 | ||
| Q3 24 | $0.00 | $0.77 | ||
| Q2 24 | $0.28 | $0.45 | ||
| Q1 24 | $0.27 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $398.9M | $919.9M |
| 总债务越低越好 | $676.9M | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $5.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资CELHRVTY
| Q4 25 | $398.9M | $919.9M | ||
| Q3 25 | $806.0M | $931.4M | ||
| Q2 25 | $615.2M | $991.8M | ||
| Q1 25 | $977.3M | $1.1B | ||
| Q4 24 | $890.2M | $1.2B | ||
| Q3 24 | $903.7M | $1.2B | ||
| Q2 24 | $903.2M | $2.0B | ||
| Q1 24 | $879.5M | $1.7B |
总债务CELHRVTY
| Q4 25 | $676.9M | — | ||
| Q3 25 | $870.5M | — | ||
| Q2 25 | $871.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CELHRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.3B | $7.6B | ||
| Q1 25 | $443.1M | $7.6B | ||
| Q4 24 | $399.9M | $7.7B | ||
| Q3 24 | $423.6M | $7.9B | ||
| Q2 24 | $415.8M | $7.9B | ||
| Q1 24 | $338.2M | $7.8B |
总资产CELHRVTY
| Q4 25 | $5.1B | $12.2B | ||
| Q3 25 | $5.3B | $12.1B | ||
| Q2 25 | $3.8B | $12.4B | ||
| Q1 25 | $1.9B | $12.4B | ||
| Q4 24 | $1.8B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | $1.6B | $13.4B |
负债/权益比CELHRVTY
| Q4 25 | 0.57× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-119.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-130.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -18.0% | 21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 2.6% |
| 现金转化率经营现金流/净利润 | -4.83× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $323.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CELHRVTY
| Q4 25 | $-119.4M | $182.0M | ||
| Q3 25 | $331.8M | $138.5M | ||
| Q2 25 | $43.7M | $134.3M | ||
| Q1 25 | $103.4M | $128.2M | ||
| Q4 24 | $75.7M | $174.2M | ||
| Q3 24 | $12.9M | $147.9M | ||
| Q2 24 | $39.6M | $158.6M | ||
| Q1 24 | $134.6M | $147.6M |
自由现金流CELHRVTY
| Q4 25 | $-130.0M | $161.8M | ||
| Q3 25 | $321.5M | $120.0M | ||
| Q2 25 | $35.5M | $115.5M | ||
| Q1 25 | $96.4M | $112.2M | ||
| Q4 24 | $70.3M | $149.8M | ||
| Q3 24 | $8.7M | $125.6M | ||
| Q2 24 | $30.4M | $136.6M | ||
| Q1 24 | $130.1M | $129.7M |
自由现金流率CELHRVTY
| Q4 25 | -18.0% | 21.0% | ||
| Q3 25 | 44.3% | 17.2% | ||
| Q2 25 | 4.8% | 16.0% | ||
| Q1 25 | 29.3% | 16.9% | ||
| Q4 24 | 21.2% | 20.5% | ||
| Q3 24 | 3.3% | 18.4% | ||
| Q2 24 | 7.6% | 19.7% | ||
| Q1 24 | 36.6% | 20.0% |
资本支出强度CELHRVTY
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 1.4% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 2.1% | 2.4% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 2.3% | 3.2% | ||
| Q1 24 | 1.3% | 2.7% |
现金转化率CELHRVTY
| Q4 25 | -4.83× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 0.44× | 2.49× | ||
| Q1 25 | 2.33× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.03× | 1.57× | ||
| Q2 24 | 0.50× | 2.87× | ||
| Q1 24 | 1.73× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CELH
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
